![Matthew John Andrew Wood](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Matthew John Andrew Wood
Founder at Pepgen Ltd.
Network origin in Matthew John Andrew Wood first degree
Entity | Entity type | Industry | |
---|---|---|---|
Pepgen Ltd.
![]() Pepgen Ltd. Packaged SoftwareTechnology Services Pepgen Ltd. engages in research and experimental development on biotechnology. The company was founded on January 25, 2018 and is headquartered in Oxford, the United Kingdom.
4
| Subsidiary | Packaged Software | 4 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Matthew John Andrew Wood via their personal network
Company | Sector | Related people | Main position |
---|---|---|---|
GILEAD SCIENCES, INC. | Biotechnology | Chief Tech/Sci/R&D Officer | |
Adheron Therapeutics, Inc.
![]() Adheron Therapeutics, Inc. BiotechnologyHealth Technology Adheron Therapeutics, Inc. discovers and develops therapeutic drugs. The firm offers Cadherin-11 antagonists for the treatment of rheumatoid arthritis and fibrotic diseases including pulmonary fibrosis and skin fibrosis. The company was founded by David Lee, Michael B. Brenner, and David L. Castaldi in 2006 and is headquartered in Berkeley, CA. | Biotechnology | Founder | |
RA PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
University of Oxford | College/University | Undergraduate Degree | |
University of Cambridge | College/University | Graduate Degree | |
McGill University | College/University | Doctorate Degree | |
University College London | College/University | Doctorate Degree | |
The University of Western Australia | College/University | Undergraduate Degree | |
AKEBIA THERAPEUTICS, INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Cydan LLC
![]() Cydan LLC Medical DistributorsDistribution Services Cydan LLC operates as an orphan drug accelerator that identifies and de-risks programs. The firm's model evaluates programs for treating rare diseases with unmet medical need and is aimed at creating new companies to develop those therapies. The company was founded by James G. McArthur in 2013 and is headquartered in Cambridge, MA. | Medical Distributors | Founder | |
The Friedreich's Ataxia Research Alliance
![]() The Friedreich's Ataxia Research Alliance Information Technology ServicesTechnology Services The Friedreich's Ataxia Research Alliance provides patient registry services. The private company is based in Downingtown, PA. | Information Technology Services | Director/Board Member | |
Vtesse, Inc.
![]() Vtesse, Inc. BiotechnologyHealth Technology Vtesse, Inc. provides novel drugs for life-threatening rare diseases. It developed VTS-270, a modified form of cyclodextrin that has been evaluated in preclinical and clinical studies at institutes within the National Institutes of Health (NIH) to treat patients with Niemann-Pick Disease Type C (NPC). The firm is working with the NIH and other leading academic centers to advance clinical study of VTS-270 for NPC, and to conduct pre-clinical discovery and development of other novel drugs for NPC and other LSDs. The company was founded by Ben Machielse in 2015 and is headquartered in Gaithersburg, MD. | Biotechnology | Founder | |
NightstaRx Ltd.
![]() NightstaRx Ltd. Medical/Nursing ServicesHealth Services NightstaRx Ltd. develops and commercializes therapies for retinal dystrophies. It offers retinal gene therapy that provides one-time cure for choroideremia (a rare inherited cause of blindness) and other retinal dystrophies. The company was founded by Robert MacLaren, Miguel Seabra, and Matthew During in January 2014 and is headquartered in London, the United Kingdom. | Medical/Nursing Services | Director/Board Member | |
NIGHTSTAR THERAPEUTICS PLC | Pharmaceuticals: Major | Director/Board Member | |
Theolytics Ltd.
![]() Theolytics Ltd. BiotechnologyHealth Technology Theolytics Ltd. engages in research and experimental development on biotechnology. The company is headquartered in Oxford, the United Kingdom. | Biotechnology | Director/Board Member | |
Evox Therapeutics Ltd.
![]() Evox Therapeutics Ltd. BiotechnologyHealth Technology Evox Therapeutics Ltd. develops and markets transformational therapeutics. The firm creates novel exosome-based biotherapeutics for the treatment of various severe diseases with limited options for patients and their families. The company was founded by Matthew Wood, Per Lundin, and Samir EL Andaloussi in 2016 and is headquartered in Oxford, the United Kingdom. | Biotechnology | Director/Board Member | |
DJS Antibodies Ltd.
![]() DJS Antibodies Ltd. BiotechnologyHealth Technology DJS Antibodies Ltd. designs and discovers novel therapeutic monoclonal antibodies against G-protein-coupled receptors. The firm conducts discovery against three targets in the fields of oncology, fibrosis and vascular disease. The company was founded by David Colin Conway Llewellyn and Joseph James Illingworth and is headquartered in Bicester, the United Kingdom. | Biotechnology | Director/Board Member | |
Macrophox Ltd.
![]() Macrophox Ltd. BiotechnologyHealth Technology Macrophox Ltd. engages in the provision of research and experimental development on biotechnology. The company was founded on March 12, 2018 and is headquartered in Woodstock, The United Kingdom. | Biotechnology | Director/Board Member | |
Tiburio Therapeutics, Inc.
![]() Tiburio Therapeutics, Inc. BiotechnologyHealth Technology Tiburio Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It provides novel treatments for rare neuroendocrine tumors and endocrine diseases. The company was founded by James Gregg McArthur in January 2019 and is headquartered in Cambridge, MA. | Biotechnology | Founder | |
RA Capital Management LP (Private Equity)
![]() RA Capital Management LP (Private Equity) Investment ManagersFinance RA Capital Management LP (Private Equity) (RA Capital) is a private equity & venture capital subsidiary of RA Capital Management LP founded by Peter Kolchinsky in 2004. The firm is headquartered in Boston, MA. | Investment Managers | Private Equity Investor | |
MiroBio Ltd.
![]() MiroBio Ltd. BiotechnologyHealth Technology Mirobio Ltd. operates as a biologics company focusing on autoimmune and inflammatory disorders. The firm develops antibody modulators of immune cell receptors, an approach that has potential across a range of diseases, with an initial focus on auto-immune disease. The company was founded by Richard Cornall and Simon Davis on October 8, 2018 and is headquartered in Oxford, the United Kingdom. | Biotechnology | Director/Board Member | |
T-Cure Bioscience, Inc.
![]() T-Cure Bioscience, Inc. BiotechnologyHealth Technology T-Cure Bioscience, Inc. is an innovative immuno-oncology company based in Sherman Oaks, CA. The private company maintains a pipeline of TCR under clinical and pre-clinical development targeting HERV-E, KK-LC-1, NY-ESO-1, and other antigens associated with solid tumors of significant unmet medical needs, including kidney cancer, breast cancer, lung cancer, gastric cancer, ovarian cancer, liver cancer, pancreatic cancer, sarcoma, and glioblastoma. The CEO of the company is Gang Zeng. | Biotechnology | Director/Board Member | |
PEPGEN INC. | Biotechnology | Chief Executive Officer Chairman Founder | |
BARINTHUS BIOTHERAPEUTICS PLC | Pharmaceuticals: Major | Director/Board Member | |
Tin Alley Ventures
![]() Tin Alley Ventures Investment ManagersFinance Tanarra Ventures Pty Ltd (Tanarra Ventures) is a venture capital firm subsidiary of Tanarra Group Pty Ltd founded in 2005 by John Wylie. The firm is headquartered in Melbourne, Australia. | Investment Managers | Private Equity Investor |
Statistics
International
United States | 17 |
United Kingdom | 12 |
Australia | 3 |
Canada | 2 |
Sectoral
Health Technology | 21 |
Consumer Services | 6 |
Finance | 3 |
Distribution Services | 2 |
Technology Services | 2 |
Operational
Director/Board Member | 17 |
Chief Tech/Sci/R&D Officer | 7 |
Founder | 7 |
Corporate Officer/Principal | 4 |
Undergraduate Degree | 4 |
Most connected contacts
Insiders | |
---|---|
James McArthur | 15 |
Andrew James Mclean | 10 |
Ramin Farzaneh-Far | 9 |
Caroline Godfrey | 2 |
- Stock Market
- Insiders
- Matthew John Andrew Wood
- Company connections